Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 2400 for:    prostate cancer AND Urogenital | ( Map: United States )

Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate (HypoFX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01868386
Recruitment Status : Active, not recruiting
First Posted : June 4, 2013
Last Update Posted : November 25, 2019
Sponsor:
Information provided by (Responsible Party):
Timothy Showalter, MD, University of Virginia

Brief Summary:

Radiation therapy is one of the standard treatments for men with prostate cancer who have detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after surgery. When radiation therapy is given to patients who have an increase in PSA after surgery, it is called "salvage radiation therapy". Currently the standard radiation therapy course length for this type of cancer is around 7 ½ -8 weeks. Sometimes, radiation therapy after prostate removal causes unpleasant side effects. A shorter course of radiation therapy, known as a "hypofractionated" course, gives fewer but higher doses of radiation than standard radiation.

The purpose of this study is to test the safety of a shorter course of radiation therapy at progressively lower dose levels and shorter lengths of treatment (hypofractionated) with patients who have had their prostate removed. The study will assess whether the hypofractionated course works better without causing additional side effects to the remaining cancer cells in the prostate bed.


Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: Hypofractionated therapy Phase 1 Phase 2

Detailed Description:

Primary Objectives:

To determine the shortest dose-fractionation schedule (Dose Schedule) with acceptable grade ¡Ã 3 GU/GI toxicity rate for salvage HypoFx RT to maintain a constant, high BED for prostate cancer response while reducing the BED for late GU and GI toxicity

To assess health-related quality of life (HRQOL) of the recommended Dose Schedule of salvage HypoFx RT by demonstrating no significant change in 1-year disease specific QoL, as compared to baseline

Secondary Objectives:

To evaluate and characterize the acute and late genitourinary (GU) and gastrointestinal (GI) adverse effects associated with postoperative, hypofractionated radiation therapy.

To evaluate biochemical failure rate, defined separately as nadir plus 2 ng/mL and as three consecutive rises in PSA, at 2 years after hypofractionated, post-prostatectomy radiation therapy.

To evaluate health utilities at 1 year after HypoFx salvage RT, as measured by the EQ-5D instrument.

To evaluate changes in sexual domain of EPIC quality of life instrument at 1 year after HypoFx salvage RT.

To evaluate the treatment burden for patients undergoing salvage HypoFx RT, in order to examine whether HypoFx RT results in less burdensome treatment for patients, as measured by patient-reported direct and indirect (i.e., transportation) health care costs and lost productivity due to treatment, as evaluated by the Work Productivity and Activity Impairment Questionnaire¢-General Health (WPAI-GH).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial
Study Start Date : April 2013
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Dose Level 1
Hypofractionated therapy, 26 treatments at 2.5 Gy
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Experimental: Dose Level 2
Hypofractionated therapy, 20 treatments at 2.83Gy
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Experimental: Dose Level 3
Hypofractionated therapy,15 treatments at 3.36 Gy
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm

Experimental: Dose Level 4
Hypofractionated therapy, 10 treatments at 4.26 Gy
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm




Primary Outcome Measures :
  1. Dose limiting toxicity [ Time Frame: over a period of 2 years ]
    Incidence of GU (genitourinary) and GI (gastrointestinal) toxicities of CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or greater

  2. Quality of life measure [ Time Frame: over a period of 2 years ]
    To compare quality of life post-procedure from baseline


Secondary Outcome Measures :
  1. Biochemical failure rate [ Time Frame: over a period of 2 years ]
    A biochemical failure is defined as an increase in prostate serum antigen concentration to nadir plus 2ng/mL or 3 consecutive increases in PSA


Other Outcome Measures:
  1. Acute and late GU and GI toxicity [ Time Frame: over a period of two years ]
  2. Health Utilities [ Time Frame: 1 year after radiation treatment ]
  3. EPIC Prostate Cancer-Specific QOL instrument [ Time Frame: over a period of two years ]
    looking at changes in sexual and hormonal domains

  4. Ancillary financial burden [ Time Frame: over a period of two years ]
    estimating out-of-pocket costs and lost wages for patients during treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of prostate adenocarcinoma and
  • have had a prostatectomy
  • have detectable PSA
  • 18 years of age or older

Exclusion Criteria:

  • are receiving chemotherapy or other agents intended for cancer treatment
  • history of rectal surgery or lower gastrointestinal bleed
  • history of bleeding diathesis or abnormal sensitivity to ionizing radiation
  • had prior pelvic irradiation or are scheduled to receive pelvic nodal irradiation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01868386


Locations
Layout table for location information
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Southwest Virginia Regional Cancer Center
Norton, Virginia, United States, 24273
Virginia Commonwealth University
Richmond, Virginia, United States, 23220
Sponsors and Collaborators
Timothy Showalter, MD
Investigators
Layout table for investigator information
Principal Investigator: Timothy Showalter, MD University of Virginia School of Medicine

Layout table for additonal information
Responsible Party: Timothy Showalter, MD, Assistant Professor, Radiation Oncology, University of Virginia
ClinicalTrials.gov Identifier: NCT01868386     History of Changes
Other Study ID Numbers: 16604
First Posted: June 4, 2013    Key Record Dates
Last Update Posted: November 25, 2019
Last Verified: November 2019
Keywords provided by Timothy Showalter, MD, University of Virginia:
Radiotherapy, hypofractionated
Salvage therapy
Radiotherapy, adjuvant
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases